J. Nalunjogi

Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study

R. Duarte, G. Sotgiu, Simon Tiberi, 2023, International Journal of Infectious Diseases.

Cardiovascular risk factors among people with drug-resistant tuberculosis in Uganda

M. Nabwana, W. Muttamba, W. Worodria, 2022, BMC Cardiovascular Disorders.

Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda

W. Katagira, I. Kimuli, M. Joloba, 2020, Open forum infectious diseases.

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

L. Rigouts, K. Sanders, M. Gurumurthy, 2022, The Lancet.

Characteristics and phenotypes of a COPD cohort in Uganda.

W. Katagira, L. Mugenyi, T. Siddharthan, 2023, medRxiv.

Perceptions of Adolescents and Health Workers Towards Adolescents’ TB Diagnosis in Central Uganda: A Cross-Sectional Qualitative Study

W. Muttamba, I. Kimuli, B. Kirenga, 2021, Risk management and healthcare policy.

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

W. Katagira, I. Kimuli, M. Joloba, 2021, Journal of clinical tuberculosis and other mycobacterial diseases.

Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study

W. Muttamba, M. Joloba, B. Kirenga, 2019, PloS one.